Dr Matossian discusses the current unmet needs in drug delivery for cataract and intraocular surgery, including the problems that patients may encounter with post-surgical topical regimens and the issues that can result if patients do not successfully adhere to their eyedrop regimens.1/4 Next Interview
Dr Stonecipher will consider which types of patients are suitable candidates for treatment with dexamethasone intraocular suspension and what are the key facts that patients should know before instillation. He will also outline the main advantages of dexamethasone intraocular suspension over topical eyedrops.2/4 Next Interview
Dr Donnenfeld will summarise the clinical trial evidence available to support the efficacy and safety of dexamethasone intraocular suspension in the treatment of post-surgical inflammation, and describe the technique that he uses to instil dexamethasone intraocular suspension into the eye.3/4 Next Interview
In this interview, Dr Hovanesian provides guidance on the optical way to instil dexamethasone intraocular suspension, including tips on how to ensure that the substance remains in its intended position, and what the clinician should do if the dexamethasone intraocular suspension moves in front of the iris. He also outlines the potential post-operative problems that may be encountered with this procedure and how they should be addressed.4/4 Leave Feedback
Overview & Learning Objectives
Experts in cataract surgery discuss unmet needs in post-operative care and the potential benefits of intracameral corticosteroids for the management of inflammation following surgery. Personal insights are shared on the successful use of dexamethasone intraocular suspension to prevent post-operative inflammation following cataract surgery.
After watching this touchEXPERT BRIEFING, you should be able to:
- Describe the unmet needs in post-operative care for patients undergoing cataract surgery
- Identify which patients might benefit most from the use of dexamethasone intraocular suspension
- Describe the key efficacy and safety data available for dexamethasone intraocular suspension
- Understand the optimal techniques to use for successful instillation of dexamethasone intraocular suspension
- Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191–9.
- An JA, Kasner O, Samek DA, et al. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40:1857–61.
- Assil KK, Greenwood MD, Gibson A, et al. Dropless cataract surgery: modernizing perioperative medical therapy to improve outcomes and patient satisfaction. Curr Opin Ophthalmol. 2020; doi:10.1097/ICU.0000000000000708. Online ahead of print.
- Kiernan DF. Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery. BMJ Open Ophthalmol. 2020;5:e000491.
- DEXYCU® (dexamethasone intraocular suspension) 9% full US Prescribing Information. EyePoint Pharmaceuticals, Inc. December 2018. Available at: https://dexycu.com/downloads/DEXYCU%20Prescribing%20Information_6-11-20.pdf (accessed 12 November, 2020).
- Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial. Ophthalmology. 2018;125:799–806.
- Donnenfeld ED, Solomon KD, Matossian C. Safety of IBI-10090 for inflammation associated with cataract surgery: Phase 3 multicenter study. J Cataract Refract Surg. 2018;44:1236–46.